Navigation Links
Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
Date:6/25/2008

REHOVOT, Israel and JERSEY CITY, New Jersey, June 25 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG), announced today that Tamir Kazaz, the Company's CFO for the last two and a half years, has resigned to pursue other interests. The Company has begun a search for a new Chief Financial Officer. Mr. Kazaz is expected to leave in the second half of 2008, and will support the company in its search and during the transition of his duties.

The planned acquisition of Parkway Clinical Laboratories and the anticipated launch of its first three products in the United States will expand the Company's focus from R&D into a full commercial entity. With the buildup of the commercial activities in the United States, the Company expects to increase its senior management presence in the United States.

"The entire staff at Rosetta Genomics thanks Tamir for the service that he has provided to the Company over his tenure and wishes him well in the future," said Amir Avniel, President and CEO of Rosetta Genomics.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working to develop a full range of microRNA-based
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
2. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
3. /C O R R E C T I O N -- Rosetta Genomics Ltd/
4. Rosetta Genomics Reports First Quarter 2008 Financial Results
5. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
6. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
7. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
8. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
9. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
10. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
11. Rosetta Genomics Establishes Medical Advisory Board

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...HAYWARD, Calif., Nov. 6 Intarcia T...y on its ITCA 650 (DUROS® continuous delivery... diabetes at the Ninth Annual Diabetes Technology .../www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO...natide Via ITCA 650 Lowers Plasma Glucose, HbA1c a...
(Date:11/5/2009)...GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -...s financial results for the third quarter ended Se....6 million ($0.04 per share) for the three months ... $6.8 million ($0.08 per share) in the comparable ...er 30, 2009, GenVec,s net loss was $14.1 million (...
(Date:11/5/2009)...SAN DIEGO, Nov. 5 Imagen...oday that William Spencer, President and CEO of Im...t the 2nd annual LD MICRO Conference on Thursday, ...n Los Angeles. ,, About LD MICRO ,, LD MICRO...ses on finding undervalued companies in the micro-...
(Date:11/5/2009)...OMAHA, Neb., Nov. 5 Tran...nounced financial results for the quarter ended Se...are presented in the tables that follow. ,, Th... loss of $366,000 or $0.01 per share for the third...,000 or $0.01 per share for the third quarter of 2...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...ugal, December 8 , - Data Highlight The Eff...ty of Life and Depressive Symptoms With Zebinix(TM...from three phase III studies presented today at th...e, USA, show that,Zebinix(TM)(1) (eslicarbazepine ... significantly reduced the frequency of partial se...
... PHILADELPHIA, Dec. 8 GlaxoSmithKline,(LSE/NYSE: ...reviously announced,tender offer to purchase all o...bs Technologies, Inc. (Nasdaq: GNLB ), for $1.30...equired withholding taxes, until 12:00 midnight,ES...offer is further extended.,The tender offer was or...
...ation announces its focus on new Rapid-Fill ASF co...(PACT) products at the 2008 American Society of He...and Exhibition beginning today at the Orange Count...WOOD, Colo., Dec. 8 Baxa Corporation is featuring... Productivity and Compliance Tools (PACT), Exacta-...
Other Biology Technology:Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 2Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 3Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 4Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 5Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 6Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 7GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc. 2Baxa Features Rapid-Fill(TM) Colored Labels, PACT(TM) Products, Exacta-Mix(TM) 2400 Compounders and Abacus(TM) Software at the ASHP Mid-Year Clinical Meeting 2Baxa Features Rapid-Fill(TM) Colored Labels, PACT(TM) Products, Exacta-Mix(TM) 2400 Compounders and Abacus(TM) Software at the ASHP Mid-Year Clinical Meeting 3
(Date:11/8/2009)... WEST LAFAYETTE, Ind. - Researchers at Purdue Univ...g damaged nerve fibers in spinal cord injuries usi...ood shortly after an accident. , The synthetic "...t 60 nanometers in diameter, or roughly 100 times ... Researchers have been studying how to deliver dru...
(Date:11/6/2009)...ee-dwelling ants generally live in harmony with th... when they run out of space in their trees of choi...ees. , The research, published in the November i... document that ants bore into live trees, and it r...between ants and plants. , Ants and certain spec...
(Date:11/5/2009)...nt State University has been awarded a training gr...ience Foundation under its Integrative Graduation ...his is the first IGERT grant to be awarded to Kent...can Recovery and Reinvestment Act of 2009, runs th...hat focuses on environment aquatic resource sensin...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Ants are friendly to some trees, but not others 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2American Airlines Employees Raise 241 Million for American Cancer Society 56600 1American Airlines Employees Raise 241 Million for American Cancer Society 56600 2American Airlines Employees Raise 241 Million for American Cancer Society 56600 3Exotic Adventure and Clean Food 3A The Adventure Cookbook 56597 1Exotic Adventure and Clean Food 3A The Adventure Cookbook 56597 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 1Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 3Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 4Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 5Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 6Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 7Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 8Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 9
... Using a "clot buster" drug normally reserved for ... room doctors were able to double the number of pa...his sudden loss of heart function occurs in more t... 93 percent of them die. , "Clot-busting agents sh...tastrophic loss of heart function," said William P...
... It turns out that the sea slug isn,t really that ...study of this charismatic orange creature,s behavi...ril 2006 issue of The Biological Bulletin. , The ...nown as Tritonia diomedea, a nudibranch mollusc sp...mportant in laboratory studies of the how the brai...
... Acid rain, the environmental consequence of burni...s, has altered soils and reduced the number of sug... to a new study led by Cornell University research...aluable tree species in the eastern United States ...st-attracting fall colors. , The study, whose l...
Other Biology News:Clot-busting drug helps revive cardiac arrest patients 2The secret lives of sea slugs 2Acid rain causing decline in sugar maples, say researchers 2Acid rain causing decline in sugar maples, say researchers 3
Goat Anti-Human RELT / TNFRSF19L Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-HOXD3 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Goat Anti-Mouse NOV / CCN3 Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Human SNAPAP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: